Mar 26, 2009 10:12 ET
Change in US Stem Cell Policy Could Create Half Billion Dollar Market
Stem Cell Therapeutics
NEW YORK, NY--(Marketwire - March 26, 2009) - The stem cell industry is
expected to thrive in the United States now that President Barack Obama has
lifted the federal funding restrictions on stem cell research, reversing the
limits imposed by President Bush on the use of embryonic stem cells more
than seven years ago. According to Kalorama Information's analysts, there
could be a $500 million dollar world market for these types of therapies by
2013; now that the world's largest healthcare economy can participate in
development.
Leading life science market research publisher Kalorama Information notes in
its new report "Stem Cell Therapeutics Markets" that under a best case
scenario where therapies are successful, regulatory acceptance is expedient
and insurers cover new therapies, the market could grow over thirty times
its estimated size of $16.4 million in 2008.
"Since there are just a few products in this area now, our analysts have
used a bottom-up model to make forecasts, based on disease incidence and a
gradual replacement of current therapies," said Bruce Carlson, publisher for
Kalorama information. "In the past, analysts have utilized models like this
to predict monoclonal antibody and cancer vaccine markets, before viable
products appeared."
Kalorama estimates that half of stem cell therapeutics revenue will be in
cardiovascular disease, with lung disease, cancer and diabetes treatments
making up the lion's share of the rest.
The previous lack of funding for basic research, compared with the
technological challenges that must be overcome, has resulted in very limited
approvals of new drug therapies that involve stem cells, despite strong
potential. As of the end of 2007, there were no approved treatments or human
trials using embryonic stem cells in the U.S. Any existing therapies were
typically in the form of stem cell transplants using either bone marrow or
blood stem cells for oncological conditions.
"This situation has allowed other countries to take the lead," noted
Carlson. "The UK is responsible for many of the advances in stem cell
technology, and both China and Singapore, with some of the most
unrestrictive embryonic stem cell research policies in the world, have
emerged in this area."
But things should change with the new federal policies and America's gain
may be Europe and Asia's loss, since money from American companies has been
funding many projects abroad, some of which will likely relocate. Still,
despite a short drop in European and Asian projects, the U.S. is the world's
largest healthcare market which should alleviate any loss in global
revenues.
Kalorama Information's new report, "Stem Cell Therapeutics Markets," breaks
down forecasted revenues and procedure volumes for stem cell therapeutics in
a variety of disease areas, discusses issues and trends, and reviews current
and developing therapies. For further information visit:
http://www.kaloramainformation.com/redirect.asp?progid=68002&productid=2021959
Rayilyn Brown
Director AZNPF
Arizona Chapter National Parkinson Foundation
rbrown@xxxxxxxxx
----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:listserv@xxxxxxxxxxxxxxxxxxxx
In the body of the message put: signoff parkinsn
